All articles by Michelle Moore

Michelle Moore

Michelle Moore joined Medical Device Network in 2023 as a trainee healthcare reporter. With a background in medical science and economics, Michelle has experience working on medical and socioeconomic research projects. She is interested in molecular biology, personalised medicine and how artificial intelligence is changing the face of healthcare. Michelle holds a BSc in Biomedical Science and an MSc in Molecular Medicine, both from the University of Sheffield, as well as an MSc(Res) in Medicine and Economics from the University of St Andrews.

Aerin reports positive results for VivAer

The study has demonstrated 90% patient improvement, sustained for two years.

OneStudyTeam customers hit more than 7,000

The company’s mission is to remove clinical trial operations as the bottleneck in delivering new therapies to patients.

Arthrosi wins $75m in Series D financing

The financing round was led by Guangrun Health Industry and supported by Reichstein Biotech.

Callidatas’ drug setanaxib shows promising results

While the data was promising, caution was advised due to the small sample size and population heterogeneity.

Skyelarke makes public significant changes to SkyePay

The SkyePay system allows patients to receive payments for participating in clinical trials.

Pulmatrix submits IND application for PUR3100

The US-based biopharmaceutical company has presented an IND application to FDA for its orally inhaled dry powder.

Acasti appoints WuXi to conduct STRIVE-ON trial

The trial will include approximately 100 patients hospitalised for aneurysmal subarachnoid haemorrhage.

Alphyn releases data from its Phase 2a trial of AB-101a

The biologics company has released data on its trial for atopic dermatitis treatment.

Celltrion presents infliximab data at ECCO Congress

The subcutaneous drug could be used to treat patients with Crohn’s disease and ulcerative colitis.

Cerecin presents findings from Phase II trial for tricaprilin

The findings show that the treatment might benefit those experiencing migraine.